Cholesterol and omega-3 fatty acids inhibit Na, K-ATPase activity in human endothelial cells.
We have investigated the effects of cholesterol and omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexenoic acid (DHA) on Na, K-ATPase activity in human endothelial cells (HUVEC). Cultured HUVEC were incubated for 18 h with pure egg phosphatidylcholine (PC), or cholesterol-enriched liposomes (4 mg PC/ml). EPA and DHA alpha-tocopherol-acetate were emulsified with PC and incubated with HUVEC (10 mM). Na, K-ATPase and 5'-nucleotidase activities were determined using the coupled assay method on microsomal fractions obtained from cultured cells using non treated cells as control. Cholesterol enrichment significantly reduced both Na, K-ATPase and 5'-nucleotidase activities by a similar level (- 40%), whereas pure phospholipid liposomes inhibited this activity only by 22%. The dose-response curves of Na, K-ATPase activity were all biphasic assuming the presence of two independent sites exhibiting different affinities for ouabain of nM and microM respectively. The cholesterol induced inhibitory effect was greater for low affinity sites (-54%) as compared to that of the high affinity sites (-24%) whereas omega-3 fatty acids reduced the activity of both sites by 22%. Short term effects of EPA and DHA on Na, K-ATPase activity were determined by incubating microsomal fractions from untreated cells with various concentrations of free fatty acids (from 1 to 200 microM) for 20 min. Both EPA and DHA significantly reduced Na, K-ATPase activity but inhibition by EPA seems to be more effective than DHA. These results suggest that cholesterol and omega-3 fatty acids reduce Na, K-ATPase activity in HUVEC.
Mayol
V
V
Laboratoire de Recherche Cardiologique, Faculté de Médecine, IFR Jean Roche, Université de la Méditerranée, Marseille, France.
Duran
M J
MJ
Gerbi
A
A
Dignat-George
F
F
Lévy
S
S
Sampol
J
J
Maixent
J M
JM
D002462:Cell Membrane / Q000187:drug effects / Q000201:enzymology / Q000648:ultrastructure; D002478:Cells, Cultured; D002784:Cholesterol / Q000494:pharmacology*; D004281:Docosahexaenoic Acids / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015118:Eicosapentaenoic Acid / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000201:enzymology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D006801:Humans; D008861:Microsomes / Q000187:drug effects / Q000201:enzymology / Q000648:ultrastructure; D010042:Ouabain / Q000494:pharmacology; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014461:Ultracentrifugation; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000201:enzymology
D004791:Enzyme Inhibitors; D015525:Fatty Acids, Omega-3; D004281:Docosahexaenoic Acids; D010042:Ouabain; D002784:Cholesterol; D015118:Eicosapentaenoic Acid; D000254:Sodium-Potassium-Exchanging ATPase